Novavax (NVAX) has 'substantial doubt' about its future. Caleb Silver discusses NVAX as its earnings were released February 28th. NVAX's adjusted EPS came in at -$2.28 versus an estimated -$0.92 and its revenue came in at $357.40M versus an estimated $377.64M. He talks about how NVAX warned of funding concerns and plans to reduce spending. He also goes over iShares Biotechnology ETF (IBB). Tune in to find out more about the stock market today.
Trading 360
03 Mar 2023
SHARE
Morning Trade Live
14 Dec 2023
Morning Trade Live
13 Dec 2023
Market On Close
30 Nov 2023
Market On Close
09 Jan 2024
Market On Close
01 Dec 2023
Trading 360
30 Jan 2024